Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ocak 2024 | 0 |
| Şubat 2024 | 0 |
| Mart 2024 | 0 |
| Nisan 2024 | 0 |
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
